

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Att'y Dkt. 2752-15

MAERTENS et al.

C# M#

Serial No. 09/638,693


Group Art Unit: Unassigned

Filed: August 15, 2000

Examiner: Unassigned

Date: May 17, 2001

Title: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC AGENTS

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED

JUN 08 2001

TECH CENTER 1600/2900

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment	42	minus highest number					
previously paid for	44	(at least 20) =	0	x	\$ 18.00		

MARK OFF

\$ 0.00

Independent claims after amendment	18	minus highest number					
previously paid for	20	(at least 3) =	0	x	\$ 80.00		

\$ 0.00

If proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)							
--	--	--	--	--	--	--	--

\$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months)							
--	--	--	--	--	--	--	--

\$ 0.00

Terminal disclaimer enclosed, add \$ 110.00							
---	--	--	--	--	--	--	--

\$ 0.00

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$710.00)							
---	--	--	--	--	--	--	--

\$ 0.00

☐ Please enter the previously unentered, filed☐ Submission attached**Subtotal** \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract							
---	--	--	--	--	--	--	--

-\$ 0.00

☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)							
--	--	--	--	--	--	--	--

\$ 0.00

Assignment Recording Fee (\$40.00)							
------------------------------------	--	--	--	--	--	--	--

\$ 0.00

Other:							
--------	--	--	--	--	--	--	--

0.00


**TOTAL FEE ENCLOSED** \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:eaw

NIXON & VANDERHYTE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: \_\_\_\_\_



RECEIVED

JUN 08 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

In re Patent Application of

**MAERTENS et al.**

Atty. Ref.: **2752-15**

Serial No. **09/638,693**

Group: **Unassigned**

Filed: **August 15, 2000**

Examiner: **Unassigned**

For: **NEW SEQUENCES OF HEPATITIS C VIRUS  
GENOTYPES AND THEIR USE AS THERAPEUTIC AND  
DIAGNOSTIC AGENTS**

\* \* \* \* \*

**May 17, 2001**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

Preliminarily amend the above-identified application as follows.

**IN THE CLAIMS**

Amend the claims as follows.

✓ ~~24-55~~  
Cancel claims ~~24-55~~, without prejudice.

Insert the following claims:

*Sub 1/17* ~~56~~ --56. (new) An isolated polypeptide or peptide consisting of 5 or more contiguous amino acids selected from at least one HCV polypeptide or peptide selected from the group consisting of:

an HCV type 3a polypeptide or peptide selected from the region spanning positions 140 to 319 of the Core/E1 region of HCV type 3a;